Fuzionaire Diagnostics, a radiopharmaceuticals company, has changed its name to Fuzionaire Theranostics, Inc. (Fuzionaire Tx) to reflect its pipeline of paired fluorine-18 PET diagnostics and radioligand therapies for cancer treatment. The company's HetSiFA® platform allows for rapid prototyping of peptide-based theranostics, enabling personalized therapeutic doses for each cancer patient. Fuzionaire Tx's first theranostic program targets prostate cancer by using a chemically identical and scalable 18F/ lutetium-177 (177Lu) theranostic pair that targets the gastrin-releasing peptide receptor (GRPR). The company is also collaborating with McGill University, McMaster University, and Paraza Pharma, among others, to advance its programs for lung cancer and PSMA/GRPR-positive prostate cancer.
Mon, 31 Jul 2023 12:00:00 GMT | Yahoo Finance